Advice
Following an abbreviated submission
lamivudine/zidovudine fixed dose combination (Combivir) in antiretroviral combination therapy is accepted for use within NHS Scotland for the treatment of Human Immunodeficiency Virus Type 1 (HIV-1) in paediatric patients weighing 14kg to 30kg.
This combination is listed in the British National Formulary for Children for the treatment of HIV infection. It was previously licensed for use in adults and adolescents weighing at least 30kg. The availability of both the combination product and its active ingredients pre-date the establishment of the Scottish Medicines Consortium.
Download detailed advice57KB (PDF)
Medicine details
- Medicine name:
- lamivudine / zidovudine (Combivir)
- SMC ID:
- 569/09
- Indication:
- HIV infection (paediatric patients).
- Pharmaceutical company
- GlaxoSmithKline UK Ltd
- BNF chapter
- Infections
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 07 September 2009